Identification of antibody targets associated with lower HIV viral load and viremic control
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0305976 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Wendy Grant-McAuley und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. Hauptthemen laut MEDLINE: Viral Load, HIV Infections, HIV Antibodies, Viremia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, U.S. President’s Emergency Plan for AIDS Relief.
Abstract (Originalsprache)
Background
High HIV viral loads (VL) are associated with increased morbidity, mortality, and on-going transmission. HIV controllers maintain low VLs in the absence of antiretroviral therapy (ART). We previously used a massively multiplexed antibody profiling assay (VirScan) to compare antibody profiles in HIV controllers and persons living with HIV (PWH) who were virally suppressed on ART. In this report, we used VirScan to evaluate whether antibody reactivity to specific HIV targets and broad reactivity across the HIV genome was associated with VL and controller status 1–2 years after infection.
Methods
Samples were obtained from participants who acquired HIV infection in a community-randomized trial in Africa that evaluated an integrated strategy for HIV prevention (HPTN 071 PopART). Controller status was determined using VL and antiretroviral (ARV) drug data obtained at the seroconversion visit and 1 year later. Viremic controllers had VLs 2,000 copies/mL at both visits. Both groups had no ARV drugs detected at either visit. VirScan testing was performed at the second HIV-positive visit (1–2 years after HIV infection).
Results
The study cohort included 13 viremic controllers and 64 non-controllers. We identified ten clusters of homologous peptides that had high levels of antibody reactivity (three in gag, three in env, two in integrase, one in protease, and one in vpu). Reactivity to 43 peptides (eight unique epitopes) in six of these clusters was associated with lower VL; reactivity to six of the eight epitopes was associated with HIV controller status. Higher aggregate antibody reactivity across the eight epitopes (more epitopes targeted, higher mean reactivity across all epitopes) and across the HIV genome was also associated with lower VL and controller status.
Conclusions
We identified HIV antibody targets associated with lower VL and HIV controller status 1–2 years after infection. Robust aggregate responses to these targets and broad antibody reactivity across the HIV genome were also associated with lower VL and controller status. These findings provide novel insights into the relationship between humoral immunity and viral containment that could help inform the design of antibody-based approaches for reducing HIV VL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
- Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
- Quantitative Sciences Division, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, United States of America.
ORCID-Profile: Peter Bock, Kwame Shanaube, Sue-Ann Meehan, Susan H Eshleman
Förderung
- National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
- U.S. President’s Emergency Plan for AIDS Relief
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- 3ie
- Bill and Melinda Gates Foundation
- National Institute on Drug Abuse
- National Institute of Mental Health
Zitieren
APA
Grant-McAuley, W., Morgenlander, W. R., Ruczinski, I., Kammers, K., Laeyendecker, O., Hudelson, S. E., Thakar, M., Piwowar-Manning, E., Clarke, W., Breaud, A., Ayles, H., Bock, P., Moore, A., Kosloff, B., Shanaube, K., Meehan, S. A., van Deventer, A., Fidler, S., Hayes, R., …, & HPTN 071 (PopART) Study Team (2024). Identification of antibody targets associated with lower HIV viral load and viremic control. PLOS ONE. https://doi.org/10.1371/journal.pone.0305976
Vancouver
Grant-McAuley W, Morgenlander WR, Ruczinski I, Kammers K, Laeyendecker O, Hudelson SE, et al. Identification of antibody targets associated with lower HIV viral load and viremic control. PLOS ONE. 2024. doi:10.1371/journal.pone.0305976
BibTeX
@article{GrantMcAuley2024,
author = {Grant-McAuley, Wendy and Morgenlander, William R and Ruczinski, Ingo and Kammers, Kai and Laeyendecker, Oliver and Hudelson, Sarah E and Thakar, Manjusha and Piwowar-Manning, Estelle and Clarke, William and Breaud, Autumn and Ayles, Helen and Bock, Peter and Moore, Ayana and Kosloff, Barry and Shanaube, Kwame and Meehan, Sue-Ann and van Deventer, Anneen and Fidler, Sarah and Hayes, Richard and Larman, H Benjamin and Eshleman, Susan H and HPTN 071 (PopART) Study Team, HPTN 071 (PopART) Study Team},
title = {Identification of antibody targets associated with lower HIV viral load and viremic control},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0305976}
}
EUVIMED